Story
Moroccan All Shares Index Closes 0.34% Lower on Banking, Mining Weakness
Summary
Morocco's benchmark stock index ended Wednesday's session in negative territory, weighed down by losses in the banking, utilities, and mining sectors. Declining stocks outnumbered advancers on the Casablanca Stock Exchange.
Morocco's benchmark stock index, the Moroccan All Shares (MASI), declined at the close of trading on Wednesday, finishing the session down 0.34%. The drop was primarily driven by sector-specific weakness, with notable losses recorded in the utilities, banking, and mining industries.
Wednesday's Trading Session
Market breadth on the Casablanca Stock Exchange was negative, as falling stocks outnumbered advancing ones by a margin of 31 to 24, according to market data. Nine stocks ended the session unchanged.
The decline was led by poor performance in several key sectors. Financials and resource-based companies were among the biggest drags on the broader market index.
Top Movers
Despite the overall market downturn, several companies posted significant gains. The top performers included:
Ad- Zellidja S.A (CSE:ZDJ), which rose 5.79%.
- M2M Group (CSE:M2M), adding 5.47%.
- Societe des Boissons du Maroc SA (CSE:SBM), which was up 3.24%.
On the other side of the ledger, the session's worst performers were led by Jet Contractors and financial firms:
- Jet Contractors (CSE:JET) fell 3.61%.
- Wafa Assurance (CSE:WAA) declined 2.83%.
- Bmce Bank (CSE:BOA) was down 2.58%.
Broader Market Context
In commodities, crude oil prices saw a significant surge, with September futures rising over 7%. In contrast, gold futures for August delivery experienced a modest decline of 0.76%. In currency markets, the Moroccan dirham weakened slightly against both the euro and the U.S. dollar.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.
Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.
Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.
J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.